Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 116, Issue 18, Pages 9008-9013
Publisher
Proceedings of the National Academy of Sciences
Online
2019-04-17
DOI
10.1073/pnas.1821510116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Familial risk of pleural mesothelioma increased drastically in certain occupations: A nationwide prospective cohort study
- (2018) Elham Kharazmi et al. EUROPEAN JOURNAL OF CANCER
- Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
- (2018) Vasiliki Panou et al. JOURNAL OF CLINICAL ONCOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes
- (2018) Marta Betti et al. GENES CHROMOSOMES & CANCER
- A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations
- (2018) Sandra Pastorino et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma
- (2018) Julija Hmeljak et al. Cancer Discovery
- A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair
- (2017) Rossella Parrotta et al. Journal of Thoracic Oncology
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
- (2016) M. Betti et al. CANCER LETTERS
- Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations
- (2016) Y. Kadariya et al. CANCER RESEARCH
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer
- (2015) Jill A. Ohar et al. CANCER RESEARCH
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
- (2015) A Napolitano et al. ONCOGENE
- Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
- (2014) Francine Baumann et al. CARCINOGENESIS
- A recurrent germlineBAP1mutation and extension of theBAP1tumor predisposition spectrum to include basal cell carcinoma
- (2014) K.A.W. Wadt et al. CLINICAL GENETICS
- Germline Mutations in Shelterin Complex Genes Are Associated With Familial Glioma
- (2014) Matthew N. Bainbridge et al. JNCI-Journal of the National Cancer Institute
- POT1 loss-of-function variants predispose to familial melanoma
- (2014) Carla Daniela Robles-Espinoza et al. NATURE GENETICS
- Germline BAP1 Mutations Predispose to Renal Cell Carcinomas
- (2013) Tatiana Popova et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
- (2013) H. Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma
- (2012) Jaine K. Blayney et al. EUROPEAN JOURNAL OF CANCER
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
- (2011) M. H. Abdel-Rahman et al. JOURNAL OF MEDICAL GENETICS
- The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
- (2011) Matthew Bott et al. NATURE GENETICS
- Germline mutations in BAP1 predispose to melanocytic tumors
- (2011) Thomas Wiesner et al. NATURE GENETICS
- Germline BAP1 mutations predispose to malignant mesothelioma
- (2011) Joseph R Testa et al. NATURE GENETICS
- Erionite exposure in North Dakota and Turkish villages with mesothelioma
- (2011) M. Carbone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
- (2010) J. W. Harbour et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started